Latest for Catecholaminergic Polymorphic Ventricular Tachycardia
See all trialsThe week in rare diseaseEach date is the day a change was posted. Open an item to see where things stand now.
- Trial sites3 new sites opened for Phase 2 Study of CRD-4730 in CPVT (Phase 2, Cardurion Pharmaceuticals)ClinicalTrials.gov
More about Catecholaminergic Polymorphic Ventricular Tachycardia
These mutations impair intracellular calcium handling and cycling, causing abnormal calcium dynamics within myocytes that trigger ectopic activity. Crucially, affected patients have structurally normal hearts and normal baseline ECGs at rest, distinguishing CPVT from other inherited arrhythmia syndromes.
Keep reading about Catecholaminergic Polymorphic Ventricular Tachycardia
Stress, exercise, or strong emotional stimuli trigger bidirectional ventricular tachycardia (alternating axis on ECG) or polymorphic ventricular tachycardia that can rapidly degenerate to ventricular fibrillation and sudden death. Symptoms typically begin in childhood or adolescence with unexplained syncope during exercise or emotional stress, though some patients remain asymptomatic until provoked.
What are the symptoms of Catecholaminergic Polymorphic Ventricular Tachycardia?
These are common symptoms of Catecholaminergic Polymorphic Ventricular Tachycardia, and how strong they are varies from person to person.
- Syncope triggered by stress, emotion, or exercise
- Polymorphic or bidirectional ventricular tachycardia
- Sudden cardiac death risk, especially in children
- Palpitations and light-headedness
- Normal baseline ECG
- Exercise-induced symptoms
Who gets Catecholaminergic Polymorphic Ventricular Tachycardia?
Catecholaminergic polymorphic ventricular tachycardia often manifests in childhood to young adulthood with stress or emotion-triggered syncope, though some patients remain asymptomatic until later years or until cardiac events occur.
The condition affects males and females. RYR2 mutations, inherited in an autosomal dominant pattern, cause about half of all cases, with ~50% of offspring of affected parents inheriting mutations. Autosomal recessive forms (CASQ2 mutations) are found primarily in certain populations including Middle Eastern and Mediterranean ancestry groups. De novo mutations account for minority of cases.
Next steps: find trials you might fitsee what is being testedget help payingget alerts
Which new Catecholaminergic Polymorphic Ventricular Tachycardia medicines are in trials?
Investigational medicines Trial Friend tracks for Catecholaminergic Polymorphic Ventricular Tachycardia, with trial results, safety findings and where each one stands.
Side effects people have reported to the FDA
Side effects people have reported to the FDA
Real-world side effect reports from the FDA Adverse Event Reporting System (FAERS). Includes both FDA-approved drugs and investigational therapies from active clinical trials. Click any drug to see what patients reported.
Loading side effect data...
Diagnosis and genetic testing
Genetic testing for Catecholaminergic Polymorphic Ventricular Tachycardia
Genetic testing can confirm a diagnosis, guide treatment decisions, and identify family members who may be at risk.
Finding labs...
Trusted Catecholaminergic Polymorphic Ventricular Tachycardia resources
Reputable organizations and medical references for learning more about Catecholaminergic Polymorphic Ventricular Tachycardia, including disease registries, foundation resources, and clinical guidelines.